Please point me to the press release where they indicated that their "advisors" were responsible for determining how and when TLD would be released.
Relying on experts to provide guidance on regulatory matters and the SAP is absolutely something they should do. Especially since they don't have anyone on the payroll that has ever brought a drug this far, at least none of their top management has ever been involved in a BLA filing, as far as I can tell.
But relying on medical and regulatory professionals' advice with respect to how and when to release TLD is not something that a reasonable investor could ever anticipate because, to my knowledge, it's never happened before.
I mean, if they are waiting to hear back from the FDA or something, because they don't want to say something that creates a regulatory problem for them, OK, I get it. But that's not the same as delaying TLD until a journal article is published, which is what the backchannels have suggested is what the company is doing, at the advice of their "advisors."
Again, it wouldn't be hard to calm the masses. A basic shareholder letter that says nothing material, but gives comfort that they are still alive and working on something important would have done the trick.
Look, we as shareholders have a right to be angry about how management has treated this company. 37 late SEC filings, 1.4 billion shares and derivative instruments outstanding when only 1.2 billion are authorized, being on the OTC with no chance of uplisting in the next couple months, etc. These are all unacceptable things that they are responsible for. It's a very poorly run company, and it's not all the fault of short sellers.
I think the hardest thing about holding this stock and not selling for a modest gain is that if this turns out poorly, I will have known better. It is the platform potential of this stock that is keeping me here...the understanding that if DCVAX-L works, it will work for other indications, and that should give us a value of at least $8.0 billion, as that should be a floor for any potential acquisition. But there are so many red flags that I know and understand are HUGE red flags...I'm going to be very mad at myself if I ignored the obvious warning signs and this turns out to be a bust, or the patient population is too low to justify what is already a very high pre-data release market cap, etc. My guess is that many other investors feel the same way. It is this emotional component of investing that is so tough for us retail shareholders in this particular investment, or at least it's tough for me. Something just doesn't add up here, but as I've said before, I don't think it's actually fraud, so I'm still betting that there is a small chance they have hit a home run and that whatever the delay is related to the spectacular nature of the data and not the mediocre...if TLD was a total bust, we would know.
